Sun.Feb 18, 2024

article thumbnail

AbbVie’s 24-hour Parkinson’s therapy to roll out on NHS

pharmaphorum

Around 1,000 people with Parkinson’s in England will be able to access treatment with AbbVie’s Produodopa, the first therapy delivered by a 24-hour subcutaneous infusion pump

121
121
article thumbnail

Episode 897: Is It Necessary To Monitor QTc of ICU Patients Receiving Antipsychotics for Delirium?

Pharmacy Joe

In this episode, I’ll discuss whether ICU patients benefit from daily QTc interval monitoring during antipsychotic use for delirium. Episode 897: Is It Necessary To Monitor QTc of ICU Patients Receiving Antipsychotics for Delirium? Subscribe on iTunes , Android , or Stitcher QTc prolongation is a known side effect of antipsychotic use. While the QTc itself is only a number on a sheet of paper, a prolonged QTc is often used as a surrogate marker for an increased risk of torsades.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New era for cell therapy as FDA OKs first for solid tumours

pharmaphorum

Iovance Biotherapeutics has become the first company to win FDA approval for a cell therapy used to treat a solid tumour, Amtagvi for melanoma

129
129
article thumbnail

AstraZeneca’s DKD pipeline highlights potential to differentiate in kidney disease space: GlobalData

Express Pharma

In a recent quarterly update, AstraZeneca revealed that it removed tozorakimab from its Phase II pipeline for diabetic kidney disease (DKD). The objective of the Phase IIb study was to evaluate the safety and efficacy of tozorakimab in subjects with DKD. Specifically, the Phase IIb trial was discontinued because of the efficacy data. Despite this setback, AstraZeneca is looking to differentiate in the DKD space with its pipeline drug, zibotentan.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Which pharmaceutical companies have the most drug patents in Croatia?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Croatia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Croatia? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Episode 897: Is It Necessary To Monitor QTc of ICU Patients Receiving Antipsychotics for Delirium?

Pharmacy Joe

In this episode, I’ll discuss whether ICU patients benefit from daily QTc interval monitoring during antipsychotic use for delirium. Episode 897: Is It Necessary To Monitor QTc of ICU Patients Receiving Antipsychotics for Delirium? Subscribe on iTunes , Android , or Stitcher QTc prolongation is a known side effect of antipsychotic use. While the QTc itself is only a number on a sheet of paper, a prolonged QTc is often used as a surrogate marker for an increased risk of torsades.